These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Cwirla SE; Balasubramanian P; Duffin DJ; Wagstrom CR; Gates CM; Singer SC; Davis AM; Tansik RL; Mattheakis LC; Boytos CM; Schatz PJ; Baccanari DP; Wrighton NC; Barrett RW; Dower WJ Science; 1997 Jun; 276(5319):1696-9. PubMed ID: 9180079 [TBL] [Abstract][Full Text] [Related]
3. Tyrosine 462 of the membrane-proximal F'-G' loop of murine Mpl is not essential for high-affinity binding of thrombopoietin. Sabath DF; Lin N; Sabath DE; Kaushansky K; Broudy VC Cytokine; 2000 Feb; 12(2):127-33. PubMed ID: 10671297 [TBL] [Abstract][Full Text] [Related]
4. Expression of active thrombopoietin and identification of its key residues responsible for receptor binding. Hou J; Zhan H Cytokine; 1998 May; 10(5):319-30. PubMed ID: 9619369 [TBL] [Abstract][Full Text] [Related]
5. Studies of the c-Mpl thrombopoietin receptor through gene disruption and activation. Alexander WS; Roberts AW; Maurer AB; Nicola NA; Dunn AR; Metcalf D Stem Cells; 1996; 14 Suppl 1():124-32. PubMed ID: 11012212 [TBL] [Abstract][Full Text] [Related]
6. Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists. Krause S; Schmoldt HU; Wentzel A; Ballmaier M; Friedrich K; Kolmar H FEBS J; 2007 Jan; 274(1):86-95. PubMed ID: 17147697 [TBL] [Abstract][Full Text] [Related]
8. [Expression of TPO mimetic peptide chimeric proteins with human IgG1 Fc fragments and their biological characters]. Li YX; Li C; Tao KH; Jia XH; Cheng DS; Huang PT Sheng Wu Gong Cheng Xue Bao; 2002 Jul; 18(4):424-30. PubMed ID: 12385237 [TBL] [Abstract][Full Text] [Related]
9. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Erickson-Miller CL; DeLorme E; Tian SS; Hopson CB; Stark K; Giampa L; Valoret EI; Duffy KJ; Luengo JL; Rosen J; Miller SG; Dillon SB; Lamb P Exp Hematol; 2005 Jan; 33(1):85-93. PubMed ID: 15661401 [TBL] [Abstract][Full Text] [Related]
10. Platelets release thrombopoietin (Tpo) upon activation: another regulatory loop in thrombocytopoiesis? Folman CC; Linthorst GE; van Mourik J; van Willigen G; de Jonge E; Levi M; de Haas M; von dem Borne AE Thromb Haemost; 2000 Jun; 83(6):923-30. PubMed ID: 10896250 [TBL] [Abstract][Full Text] [Related]
11. Xanthocillins as thrombopoietin mimetic small molecules. Sakai R; Nakamura T; Nishino T; Yamamoto M; Miyamura A; Miyamoto H; Ishiwata N; Komatsu N; Kamiya H; Tsuruzoe N Bioorg Med Chem; 2005 Dec; 13(23):6388-93. PubMed ID: 16115772 [TBL] [Abstract][Full Text] [Related]
12. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Li J; Xia Y; Kuter DJ Br J Haematol; 2000 Dec; 111(3):943-53. PubMed ID: 11122159 [TBL] [Abstract][Full Text] [Related]
13. Dissection of c-Mpl and thrombopoietin function: studies of knockout mice and receptor signal transduction. Gurney AL; de Sauvage FJ Stem Cells; 1996; 14 Suppl 1():116-23. PubMed ID: 11012211 [TBL] [Abstract][Full Text] [Related]
14. Biological roles for the second domain of thrombopoietin. Foster D; Lok S Stem Cells; 1996; 14 Suppl 1():102-7. PubMed ID: 11012208 [TBL] [Abstract][Full Text] [Related]
15. The Mpl receptor expressed on endothelial cells does not contribute significantly to the regulation of circulating thrombopoietin levels. Geddis AE; Fox NE; Kaushansky K Exp Hematol; 2006 Jan; 34(1):82-6. PubMed ID: 16413394 [TBL] [Abstract][Full Text] [Related]
16. Neutralization of biological activity and inhibition of receptor binding by antibodies against human thrombopoietin. Tahara T; Kuwaki T; Matsumoto A; Morita H; Watarai H; Inagaki Y; Ohashi H; Ogami K; Miyazaki H; Kato T Stem Cells; 1998; 16(1):54-60. PubMed ID: 9474748 [TBL] [Abstract][Full Text] [Related]
17. Impact of chicken thrombopoietin and its receptor c-Mpl on hematopoietic cell development. Bartunek P; Karafiat V; Bartunkova J; Pajer P; Dvorakova M; Kralova J; Zenke M; Dvorak M Exp Hematol; 2008 Apr; 36(4):495-505. PubMed ID: 18243490 [TBL] [Abstract][Full Text] [Related]
18. A family of leukemia inhibitory factor-binding peptides that can act as antagonists when conjugated to poly(ethylene glycol). Fairlie WD; Uboldi AD; Hemmings GJ; Smith BJ; Martin HM; Morgan PO; Baca M Biochemistry; 2003 Nov; 42(45):13193-201. PubMed ID: 14609330 [TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura. Newland A Semin Hematol; 2007 Oct; 44(4 Suppl 5):S35-45. PubMed ID: 18096471 [TBL] [Abstract][Full Text] [Related]
20. Normal thrombopoietin and its receptor (c-mpl) genes in children with essential thrombocythemia. Randi ML; Putti MC; Pacquola E; Luzzatto G; Zanesco L; Fabris F Pediatr Blood Cancer; 2005 Jan; 44(1):47-50. PubMed ID: 15390356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]